Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
Recruiting · NCT07359040 · Observational (researchers observe without assigning treatment) · Lead sponsor: Peking University People's Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is an exploratory clinical study focusing on the neoadjuvant treatment of non-small cell lung cancer (NSCLC). The study primarily aims to compare the efficacy and safety of Ivonescimab, a novel PD-1/VEGF bispecific antibody, with those of conventional PD-1 inhibitors. Beyond evaluating its direct therapeutic benefits, this research also seeks to elucidate the potential mechanisms underlying the enhanced efficacy of Ivonescimab. Additionally, the study will conduct secondary exploratory analyses, including the identification and validation of predictive and prognostic biomarkers, as well as multi-omics profiling to investigate the molecular mechanisms of action. Collectively, these efforts aim to provide comprehensive experimental data to support the rational clinical application of Ivonescimab and the development of precision medicine strategies for NSCLC.
Who can take part
Inclusion criteria
- Patients with non-small cell lung cancer (Stage IB-IIIB) who require radical surgery following neoadjuvant therapy.
Exclusion criteria
- Histology of other malignant tumors, including concurrent malignant tumors of other organ systems;
- Unresectable advanced disease (Stage IV) or locally advanced unresectable (Stage IIIC);
- Pregnancy or lactation;
- Insufficient sample quality;
- Severe organ dysfunction (e.g. cardiac or renal insufficiency);
- Other judgments by the Investigator that the patient should not participate in the study.
Where it is running
1 location listed.
- Peking University People's Hospital - Beijing, Beijing Municipality, China